-transparent.png){kind=logo}
We describe here the transduction of murine hematopoietic progenitor cells with the dominant selectable neomycin drug-resistance (Neo) gene using a recombinant adeno-associated virus (AAV) vector. Successful transformation of progenitor cells to drug resistance was determined to be approximately 1.5% by colony formation in the presence of geneticin sulfate (G-418). The value of AAV as an alternative to the retrovirus vector systems is discussed.
Related Publications
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
September 1994,
Blood,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
July 1993,
Experimental hematology,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
November 1985,
Science (New York, N.Y.),
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
December 2006,
Current gene therapy,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
September 2000,
Gene therapy,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
May 1996,
Human molecular genetics,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
December 1999,
Experimental neurology,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
January 2017,
Chemical senses,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
May 1998,
Australian and New Zealand journal of ophthalmology,
D LaFace, and
P Hermonat, and
E Wakeland, and
A Peck
March 2003,
The Journal of trauma,
